ISSN:
1569-8041
Keywords:
adolescence
;
ALK antigen
;
anaplasia
;
anaplastic large-cell lymphoma
;
CD30 antigen
;
child
;
diagnosis
;
Ki-1 large-cell lymphoma
;
non-Hodgkin's lymphoma
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Background: Anaplastic lymphoma kinase (ALK) is a tyrosine kinaseinappropriately expressed in lymphoid tissue involved by CD30+ anaplasticlarge-cell lymphoma (ALCL) with the translocation t(2;5)(p23;q35), whichjuxtaposes the nucleophosmin gene (NPM) with that encoding ALK, resulting ina hybrid (NPM-ALK) message. Patients and methods: A polyclonal antibody against residues of thekinase portion of NPM-ALK (designated anti-ALK 11) was tested for clinicalutility in paraffin sections of 44 cases of pediatric large-cell lymphoma(LCL) and 17 additional lymphoma cases, by streptavidin-biotin-alkalinephosphatase method. Results: Nineteen of 20 CD30+ cases (the majority exhibitinganaplastic morphology) labeled with anti-ALK 11, and 5/28 CD30− caseswere also ALK+ (3 T cells, 1 null cell, and 1 B cell). Sixteen of 17 B-cellpediatric LCLs were negative, as were 6/6 cases of Hodgkin's disease and 7/7cases of adult B-cell lymphoma. In pediatric LCLs with adequate follow-up(24/44 ALK+), there was no significant association between ALK expression andtwo-year event-free survival, similar to the finding reported previously forCD30 expression in these cases. Conclusion: We conclude that the majority of pediatric CD30+ ALCLsshow ALK overexpression, consistent with the presence of the t(2;5)-encodedNPM-ALK fusion, but that the clinical significance of this entity remainsunproven.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008293531450
Permalink
